Top

Published in:

01-04-2018 | Original Article

Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast

Authors: Valerie Cui Yun Koh, Aye Aye Thike, Nur Diyana Md Nasir, George Wai Cheong Yip, Boon Huat Bay, Puay Hoon Tan

Published in: Virchows Archiv | Issue 4/2018

Abstract

Phyllodes tumours (PTs) of the breast are uncommon fibroepithelial neoplasms comprising 0.3–1.0% of all primary breast tumours. The majority of PTs are benign and generally well managed with surgery. However, malignant PTs, and occasionally borderline PTs, can behave in a clinically aggressive manner by metastasizing to distant organs. Although distant metastasis is rare, the prognosis of patients with metastasis is dismal as many are unresponsive to standard chemotherapy and the risk of death is high. In this study, we correlated clinicopathological parameters to survival outcomes in a cohort of patients diagnosed with malignant PTs in our institution. The study cohort comprised 83 cases of malignant PTs diagnosed at the Department of Anatomical Pathology, Singapore General Hospital from 1994 to 2015. Clinicopathological features and follow-up were obtained from hospital records. Metastasis-free survival (MFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared between groups using the log-rank test. Cox regression was carried out to identify factors predictive for metastasis. Mean and median age of patients was 48 years (range 21–71 years). Tumour size measured from 30 to 220 mm (mean 90 mm, median 77 mm). Follow-up data was available for 68 patients. Mean and median follow-up was 90 and 57 months, respectively, with a maximum of 291 months. Distant metastasis occurred in 16 out of 68 patients (23.5%). The most common site of metastasis was the lung. Malignant heterologous elements were observed in 16 (19.3%) cases. Individual clinicopathological parameters had no impact on outcome. On Kaplan-Meier analysis, women with large tumours and presence of malignant heterologous elements showed trends for poorer MFS (p = 0.217 and p = 0.566, respectively). However, the combination of large tumours (≥ 90 mm) containing malignant heterologous elements disclosed significantly worse MFS (p = 0.043) and a trend for poorer OS (p = 0.238). On multivariate analysis, large tumours harbouring malignant heterologous elements independently predicted metastasis (95% CI 1.041–12.517, HR 2.434, p = 0.049). Our study demonstrates that tumour size and presence of malignant heterologous elements predicted metastasis in malignant PTs. Further work needs to be done in determining if protein biomarkers and genomic aberrations are able to additionally refine metastatic risk and define therapeutic targets.

Tan PH, Tse G, Lee A, Simpson JF, Hanby AM (2012) Fibroepithelial tumours. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours of the breast. IARC, Lyon, p 142-145

Zhang Y, Kleer CG (2016) Phyllodes tumor of the breast: histopathologic features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med 140(7):665–671. https://doi.org/10.5858/arpa.2016-0042-RA CrossRefPubMed

Mituś JW, Blecharz P, Walasek T, Reinfuss M, Jakubowicz J, Kulpa J (2016) Treatment of patients with distant metastases from phyllodes tumor of the breast. World J Surg 40(2):323–328. https://doi.org/10.1007/s00268-015-3262-7 CrossRefPubMed

Tan PH, Thike AA, Tan WJ, Thu MM, Busmanis I, Li H et al (2012) Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol 65(1):69–76. https://doi.org/10.1136/jclinpath-2011-200368 CrossRefPubMed

Tan BY, Acs G, Apple SK, Badve S, Bleiweiss I, Brogi E et al (2016) Phyllodes tumours of the breast: a consensus review. Histopathology 68(1):5–21. https://doi.org/10.1111/his.12876 CrossRefPubMedPubMedCentral

Tan PH, Jayabaskar T, Chuah KL, Lee HY, Tan Y, Hilmy M et al (2005) Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol 123(4):529–540. https://doi.org/10.1309/U6DV-BFM8-1MLJ-C1FN CrossRefPubMed

Hawkins RE, Schofield JB, Fisher C, Wiltshaw E, McKinna JA (1992) The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer 69(1):141–147CrossRefPubMed

de Roos WK, Kaye P, Dent DM (1999) Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast. Br J Surg 86(3):396–399CrossRefPubMed

Kapiris I, Nasiri N, A'Hern R, Healy V, Gui GP (2001) Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol 27(8):723–730. https://doi.org/10.1053/ejso.2001.1207 CrossRefPubMed

10.

Warrier S, Hwang S, Gibbings K, Carmalt H, O'Toole S (2015) Phyllodes tumour with heterologous sarcomatous differentiation: case series with literature review. Int J Surg Case Rep 11:91–94. https://doi.org/10.1016/j.ijscr.2015.02.009 CrossRefPubMedPubMedCentral

11.

Hallin M, Thway K (2017) Phyllodes tumor with heterologous liposarcomatous differentiation. Int J Surg Pathol 25(5):435–437. https://doi.org/10.1177/1066896917696750 CrossRefPubMed

12.

Guerrero MA, Ballard BR, Grau AM (2003) Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol 12(1):27–37CrossRefPubMed

13.

Patil Okaly GV, Devadass CW, Metikurke SH (2015) Malignant phyllodes tumor with heterologous differentiation: a rare case report. J Cancer Res Ther 11(3):651. https://doi.org/10.4103/0973-1482.137996 CrossRefPubMed

14.

Tomas D, Bujas T, Stajduhar E, Kirac P, Mijić A, Kruslin B (2007) Malignant phyllodes tumor with associated osteosarcomatous, chondrosarcomatous, and liposarcomatous overgrowth. APMIS 115(4):367–370. https://doi.org/10.1111/j.1600-0463.2007.apm_588.x CrossRefPubMed

15.

Inyang A, Thomas DG, Jorns J (2016) Heterologous liposarcomatous differentiation in malignant phyllodes tumor is histologically similar but immunohistochemically and molecularly distinct from well-differentiated liposarcoma of soft tissue. Breast J 22(3):282–286. https://doi.org/10.1111/tbj.12567 CrossRefPubMed

16.

Lyle PL, Bridge JA, Simpson JF, Cates JM, Sanders ME (2016) Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with MDM2 or CDK4 amplification. Histopathology 68(7):1040–1045. https://doi.org/10.1111/his.12898 CrossRefPubMed

17.

Liu SY, Joseph NM, Ravindranathan A, Stohr BA, Greenland NY, Vohra P et al (2016) Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol 29(9):1012–1027. https://doi.org/10.1038/modpathol.2016.97 CrossRefPubMed

18.

Barnes L, Pietruszka M (1978) Rhabdomyosarcoma arising within a cystosarcoma phyllodes: case report and review of the literature. Am J Surg Pathol 2(4):423–429CrossRefPubMed

19.

Silver SA, Tavassoli FA (1999) Osteosarcomatous differentiation in phyllodes tumors. Am J Surg Pathol 23(7):815–821CrossRefPubMed

20.

Austin RM, Dupree WB (1986) Liposarcoma of the breast: a clinicopathologic study of 20 cases. Hum Pathol 17(9):906–913CrossRefPubMed

21.

Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL et al (2005) Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol 91(3):185–194. https://doi.org/10.1002/jso.20334 CrossRefPubMed

22.

Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE et al (2000) Primary treatment of cystosarcoma phyllodes of the breast. Cancer 89(7):1502–1511CrossRefPubMed

23.

Abdalla HM, Sakr MA (2006) Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast. J Egypt Natl Canc Inst 18(2):125–133PubMed

24.

Lenhard MS, Kahlert S, Himsl I, Ditsch N, Untch M, Bauerfeind I (2008) Phyllodes tumour of the breast: clinical follow-up of 33 cases of this rare disease. Eur J Obstet Gynecol Reprod Biol 138(2):217–221. https://doi.org/10.1016/j.ejogrb.2007.08.002 CrossRefPubMed

25.

Sawalhi S, Al-Shatti M (2013) Phyllodes tumor of the breast: a retrospective study of the impact of histopathological factors in local recurrence and distant metastasis. Ann Saudi Med 33(2):162–168. https://doi.org/10.5144/0256-4947.2013.162 CrossRefPubMed

26.

Ren D, Li Y, Gong Y, Xu J, Miao X, Li X et al (2014) Phyllodes tumor of the breast: role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors. Tumour Biol 35(10):9603–9612. https://doi.org/10.1007/s13277-014-2254-9 CrossRefPubMed

27.

Wei J, Tan YT, Cai YC, Yuan ZY, Yang D, Wang SS et al (2014) Predictive factors for the local recurrence and distant metastasis of phyllodes tumors of the breast: a retrospective analysis of 192 cases at a single center. Chin J Cancer 33(10):492–500. https://doi.org/10.5732/cjc.014.10048 PubMedPubMedCentral

28.

Ward RM, Evans HL (1986) Cystosarcoma phyllodes: a clinicopathologic study of 26 cases. Cancer 58(10):2282–2289CrossRefPubMed

29.

Asoglu O, Ugurlu MM, Blanchard K, Grant CS, Reynolds C, Cha SS et al (2004) Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors. Ann Surg Oncol 11(11):1011–1017. https://doi.org/10.1245/ASO.2004.02.001 CrossRefPubMed

30.

Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S et al (2013) Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol 88(2):427–436. https://doi.org/10.1016/j.critrevonc.2013.06.005 CrossRefPubMed

31.

Al-Masri M, Darwazeh G, Sawalhi S, Mughrabi A, Sughayer M, Al-Shatti M (2012) Phyllodes tumor of the breast: role of CD10 in predicting metastasis. Ann Surg Oncol 19(4):1181–1184. https://doi.org/10.1245/s10434-011-2076-6 CrossRefPubMed

32.

Tan WJ, Thike AA, Bay BH, Tan PH (2014) Immunohistochemical expression of homeoproteins Six1 and Pax3 in breast phyllodes tumours correlates with histological grade and clinical outcome. Histopathology 64(6):807–817. https://doi.org/10.1111/his.12329 CrossRefPubMed

33.

Lim WK, Ong CK, Tan J, Thike AA, Ng CC, Rajasegaran V et al (2014) Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet 46(8):877–880. https://doi.org/10.1038/ng.3037 CrossRefPubMed

34.

Ng CC, Tan J, Ong CK, Lim WK, Rajasegaran V, Nasir ND et al (2015) MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases. J Clin Pathol 68(9):685–691. https://doi.org/10.1136/jclinpath-2015-202896 CrossRefPubMed

35.

Yoshida M, Sekine S, Ogawa R, Yoshida H, Maeshima A, Kanai Y et al (2015) Frequent MED12 mutations in phyllodes tumours of the breast. Br J Cancer 112(10):1703–1708. https://doi.org/10.1038/bjc.2015.116 CrossRefPubMedPubMedCentral

36.

Nagasawa S, Maeda I, Fukuda T, Wu W, Hayami R, Kojima Y et al (2015) MED12 exon 2 mutations in phyllodes tumors of the breast. Cancer Med 4(7):1117–1121. https://doi.org/10.1002/cam4.462 CrossRefPubMedPubMedCentral

37.

Piscuoglio S, Murray M, Fusco N, Marchiò C, Loo FL, Martelotto LG et al (2015) MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast. Histopathology 67(5):719–729. https://doi.org/10.1038/npjbcancer.2016.35 CrossRefPubMedPubMedCentral

38.

Tan J, Ong CK, Lim WK, Ng CC, Thike AA, Ng LM et al (2015) Genomic landscapes of breast fibroepithelial tumors. Nat Genet 47(11):1341–1345. https://doi.org/10.1038/ng.3409 CrossRefPubMed

39.

Nozad S, Sheehan CE, Gay LM, Elvin JA, Vergilio JA, Suh J et al (2017) Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Res Treat 162(3):597–602. https://doi.org/10.1007/s10549-017-4156-1 CrossRefPubMed

Title: Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast
Authors: Valerie Cui Yun Koh
Aye Aye Thike
Nur Diyana Md Nasir
George Wai Cheong Yip
Boon Huat Bay
Puay Hoon Tan
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 4/2018
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-017-2257-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?

Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study

Pulmonary neuroendocrine carcinomas—evidence for a spectrum of differentiation

Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics

Book Review—Pulmonary Pathology, 2nd Edition

CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8+/Foxp3+ T cells